-
Nature BE: Shengxing team at Tsinghua University and others found that thin-film silicon photodiodes can selectively activate or inhibit neural activity
Time of Update: 2022-10-31
Recently, Tsinghua University, Tsinghua University Department of Electronics, Tsinghua-IDG/McGovern Institute of Brain Science Associate Professor Sheng Xing, Chinese Academy of Sciences Shenzhen Institute of Advanced Technology, Shenzhen-Hong Kong Institute of Brain Science Innovation Institute Li Xiaojian, researcher Li Xiaojian, Beijing Institute of Technology Associate Researcher Wang Shirong, as co-corresponding authors, published in Nature Biomedical Engineering title: Bioresorbable thin-film silicon diodes for the optoelectronic excitation and inhibition of neural activities.
-
In the treatment of ulcerative colitis, it is necessary to take into account precise anti-inflammatory, efficacy and safety
Time of Update: 2022-03-09
Clinical diagnosis: UC (chronic relapsing, full colon, active, moderate), Mayo total score 9, MES score 3 Following regular treatment of 300mg of zizumab for 4 times (0, 2, 6, 14w), the patient's intermittent abdominal pain and fecal mucus symptoms were significantly improved, and the stool 1-2 times/day turned yellow .
-
CD47 meets PD-L1, mutual achievement and exploration of infinite possibilities
Time of Update: 2022-01-10
In addition, Maiwei Biologics has also deployed 6MW3411, a bispecific antibody of PD-L1 and NK cell immune checkpoint, which is the first of its kind, and is expected to enter the clinical research phase in 2022 .
-
Treat anxiety
Time of Update: 2021-12-31
Article source: Medical Rubik's Cube InfoAuthor: Shi BeiOn December 1, Bionomics announced that the US FDA granted the company a first-in-class new oral therapy BNC210 fast track designation for the treatment of acute social anxiety disorder (SAD) and other anxiety-related diseases .
-
Post "Nature
Time of Update: 2021-11-14
In a study on mice published in the journal Nature on October 13, 2021, the team identified a subset of neurons that must exist in acupuncture and moxibustion to trigger resistance through this signaling pathway.
-
J Med Chem: Dual PROTAC is here: Chinese scholars first proposed a new concept of dual-targeted degradation (Dual PROTACs) drug design
Time of Update: 2021-06-04
This research creatively proposes a new concept for the design of dual-targeted degradation drugs (Dual PROTACs), using the existing EGFR inhibitor Gefitinib and PARP inhibitor Olaparib as raw materials to synthesize different link lengths and different E3 ligases (CRBN- and VHL- ) The recruited EGFR and PARP protein dual target degradation chimeric molecules (Dual PROTACss), and successfully degrade both EGFR and PARP proteins in cancer cells at the cellular level.
-
Scientists have discovered a new anorexia hormone
Time of Update: 2021-01-26
recently, a team at Columbia University Medical Center in the United States discovered anorexia hormone called Lipocalin-2, which inhibits food intake and increases satiety.
researchers found in mice that the Lipocalin-2 hormone (LCN2) from osteoblasts inhibited food intake and acted as a signal of satiety.
-
Cancer is saved in the advanced stages, "a needle" can be cured? Oncologist: Several conditions are not suitable
Time of Update: 2020-10-20
mainly by the use of ultrasound or CT and other imaging technology guidance, the electrode needle directly into the tumor, through radio frequency energy to make the lesions local tissue produce high temperature, drying, and eventually solidified and inactivate soft tissue and tumor.
-
Clin Exp Rheumatol: Intravenous VS oral cyclophosphamide to treat the effects of systemic sclerosis on the lungs and/or skin fibrosis
Time of Update: 2020-10-12
In placebo-controlled randomized clinical trials and observational studies, both intravenous (IV) and oral (PO) cyclophosphamide (CYC) have shown beneficial effects on skin and lungs of systemic sclerosis (SSc).
analyze severity (SAEs) and non-critical adverse events and efficacy data (FVC, DLCO, mRSS changes) at the end of CYC therapy (EoT) and follow-up (FU).
-
A list of recent research advances in the journal Nature for the new coronavirus SARS-CoV-2/COVID-19 (No. 4
Time of Update: 2020-09-30
1.Nature: Revealing the structural mechanism of SARS-CoV-2 hedgehog protein binding human ACE2 receptor doi:10.1038/s41586-020-2772 In a new study, researchers from the Francis-Crick Institute in the United Kingdom found that the prickly protein (S protein) on the surface of the SARS-CoV-2 coronavirus can take at least ten different structural states when in contact with the human virus-like ACE2.
-
Water stinks? Ashland sewage treatment defoamer fragrance
Time of Update: 2020-08-18
Ashland sewage treatment defoaming agent, foaming speed, foaming effect is good, applied to pharmaceutical, paper, leather, printing and dyeing, urban sewage biological treatment process and chemical cleaning and other foaming system; It can also be used for oil drilling liquid mud system defoaming, wastewater treatment defoamer is based on modified silicon ether and modified siloxane composite, using special process refined from the excellent defoaming agent, the use of methods is simple to operate, there is no complex procedures, low cost.
-
Canadian scientists have developed a new method that can deliver cancer drugs precisely to tumors
Time of Update: 2020-07-18
recently, researchers from the University of Alberta, Canada, have modified nanoparticles to deliver anticancer drugs more accurately to colorectal cancer.
the title is "synthesis and analysis of 64Cu labeled ge11 modified polymeric mica nanoparticles for EGFR targeted molecular imaging in a colorectic cancer model".
-
Xuno Pharmaceuticals officially launched Abesta for treatment of lymphoma, renal cell carcinoma II, Phase III clinical
Time of Update: 2020-06-08
Recently, Abexinostat of Xuno Pharmaceuticals officially launched Phase II and III clinical treatment for lymphoma and renal cell carcinoma About Abestas Abes is the first candidate drug (http:
-
Treatment of COVID-19 Antibody Drugs Has More Potential than Small Molecules
Time of Update: 2020-05-30
In a March 23 issue of the Journal of the American Society for Microbiology, several treatments for new coronal drugs were published, including the well-known chloroquine/hydroxychloroquine, redsiewe
-
Novartis spinal muscular dystrophy gene therapy Zolgensma is approved by the European Union
Time of Update: 2020-05-28
Novartis gene therapy company AveXis recently announced that the European Commission (EC) has conditional approval of the gene therapy Zolgensma (onasemnogene abeparvovec) for the treatment of 5q spi
